论文部分内容阅读
目的:观察NP方案(长春瑞滨+顺铂)和GP方案(吉西他滨+顺铂)对初治的晚期非小细胞肺癌(NSCLC)的疗效和毒副反应。方法:68例晚期NSCLC(ⅢB期48例,Ⅳ期20例)随机分成NP组和GP组,入选患者接受≥2个周期NP或GP方案的化疗,比较两组不同化疗方案的近期疗效和毒副反应及1年的生存率。结果:NP和GP两组近期疗效的有效率分别为41.18%和44.12%,两组中位生存期分别为8.1和8.4个月,1年生存率分别为29.41%和32.35%。两组差异均无统计学意义(P>0.05)。毒副反应主要表现在血液和消化道反应。NP组以白细胞降低为主,GP组以血小板降低为主,对症处理均可恢复或耐受。结论:NP和GP两种化疗方案对晚期NSCLC均有较好的临床疗效,化疗毒副反应虽有所不同,但均可耐受或恢复。故NP和GP两种化疗方案均可作为晚期NSCLC的一线治疗方案。中华肿瘤防治杂志,2010,17(9):703-705
Objective: To observe the curative effect and toxicity of NP regimen (vinorelbine + cisplatin) and GP regimen (gemcitabine + cisplatin) on newly diagnosed advanced non-small cell lung cancer (NSCLC). Methods: Sixty-eight patients with advanced NSCLC (48 cases in stage ⅢB and 20 cases in stage Ⅳ) were randomly divided into NP group and GP group. The patients were enrolled in the chemotherapy of NP or GP regimen ≥2 cycles. The curative effect and toxicity of two chemotherapy regimens were compared Side effects and 1-year survival rate. Results: The effective rates of NP and GP in short-term treatment were 41.18% and 44.12% respectively. The median survival time was 8.1 and 8.4 months respectively. The 1-year survival rates were 29.41% and 32.35% respectively. There was no significant difference between the two groups (P> 0.05). Toxicity mainly in the blood and gastrointestinal reactions. NP group mainly leukopenia, GP group mainly thrombocytopenia, symptomatic treatment can be restored or tolerated. CONCLUSION: Both NP and GP chemotherapy regimens have good clinical efficacy in advanced NSCLC. Chemotherapeutic toxicities may be tolerated or recovered, although they may be different. Therefore, both NP and GP chemotherapy can be used as a first-line treatment of advanced NSCLC. Chinese Journal of Cancer Prevention and Treatment, 2010,17 (9): 703-705